![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Russia Pursues Single-Dose, Light Version of Sputnik V Vaccine
Russia Pursues Single-Dose, Light Version of Sputnik V Vaccine
![Russia on map with flag](https://www.fdanews.com/ext/resources/test/Device_Images6/RussiawithRussianFlag.gif?t=1616695725&width=430)
March 24, 2021
Russian researchers are reportedly seeking approval for a single-dose version of the Sputnik V COVID-19 vaccine and are conducting clinical trials in Russia, the United Arab Emirates and Ghana.
Peer-reviewed interim phase 3 data released last month showed the Sputnik V vaccine demonstrated nearly 92 percent efficacy as a two-dose shot.
The single-shot vaccine is meant as a temporary solution for nations with skyrocketing rates of infections.
The application for approval is reportedly based on smaller phase 1 and 2 clinical trials, and not the phase 3 trials currently under way.
Upcoming Events
-
21Oct